Cancer Diagnostics Market by Diagnostic Type, Indication, Components, End-Use - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation

List of Tables

The Global Cancer Diagnostics Market is forecasted to grow significantly, with a projected USD 29.95 billion in 2023 at a CAGR of 11.60% and expected to reach a staggering USD 65.06 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Diagnostic Type, market is studied across Biopsy, Blood Chemistry Tests, and Imaging Tests. The Blood Chemistry Tests is further studied across Complete Blood Count (CBC), Cytogenetic Analysis, Immunophenotyping, Liquid Biopsy, Sputum Cytology, Tumor Marker Tests, and Urine Cytology. The Imaging Tests is further studied across Bone Scan, CT-Scan, Magnetic Resonance Imaging (MRI), Nuclear Scan, Positron Emission Tomography (PET) Scan, Ultrasound, and X-Rays. The Imaging Tests commanded largest market share of 37.76% in 2022, followed by Biopsy.

Based on Indication, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer. The Lung Cancer commanded largest market share of 19.99% in 2022, followed by Breast Cancer.

Based on Components, market is studied across Consumables, Instruments, and Software. The Instruments commanded largest market share of 74.75% in 2022, followed by Consumables.

Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, and Research Centers. The Hospitals commanded largest market share of 52.45% in 2022, followed by Diagnostic Laboratories.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.45% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Diagnostics Market?

6. What is the market share of the leading vendors in the Global Cancer Diagnostics Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Diagnostics Market?

Product Code: MRR-436145BF8B19

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cancer Diagnostics Market, by Diagnostic Type, 2022 vs 2030
4.3. Cancer Diagnostics Market, by Indication, 2022 vs 2030
4.4. Cancer Diagnostics Market, by Components, 2022 vs 2030
4.5. Cancer Diagnostics Market, by End-Use, 2022 vs 2030
4.6. Cancer Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing burden of cancer among younger and geriatric population
  - 5.1.1.2. Rising government initiatives and campaigns for cancer awareness
  - 5.1.1.3. Favorable reimbursement framework for cancer diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
- 5.1.3. Opportunities
  - 5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
  - 5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
- 5.1.4. Challenges
  - 5.1.4.1. Inadequate and false results of cancer diagnostics
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Cancer Diagnostics Market, by Diagnostic Type

6.1. Introduction
6.2. Biopsy
6.3. Blood Chemistry Tests
- 6.3.1. Complete Blood Count (CBC)
- 6.3.2. Cytogenetic Analysis
- 6.3.3. Immunophenotyping
- 6.3.4. Liquid Biopsy
- 6.3.5. Sputum Cytology
- 6.3.6. Tumor Marker Tests
- 6.3.7. Urine Cytology
6.4. Imaging Tests
- 6.4.1. Bone Scan
- 6.4.2. CT-Scan
- 6.4.3. Magnetic Resonance Imaging (MRI)
- 6.4.4. Nuclear Scan
- 6.4.5. Positron Emission Tomography (PET) Scan
- 6.4.6. Ultrasound
- 6.4.7. X-Rays

7. Cancer Diagnostics Market, by Indication

7.1. Introduction
7.2. Bladder Cancer
7.3. Blood Cancer
7.4. Breast Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Pancreatic Cancer
7.10. Prostate Cancer
7.11. Skin Cancer

8. Cancer Diagnostics Market, by Components

8.1. Introduction
8.2. Consumables
8.3. Instruments
8.4. Software

9. Cancer Diagnostics Market, by End-Use

9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals
9.4. Research Centers

10. Americas Cancer Diagnostics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cancer Diagnostics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cancer Diagnostics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
  - 13.3.1.1. Biocare Medical Acquires Empire Genomics
  - 13.3.1.2. Thermo Fisher ties up $2.6B deal for The Binding Site
  - 13.3.1.3. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
  - 13.3.1.4. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
  - 13.3.1.5. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
- 13.3.2. Agreement, Collaboration, & Partnership
  - 13.3.2.1. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
  - 13.3.2.2. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
  - 13.3.2.3. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
  - 13.3.2.4. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
- 13.3.3. New Product Launch & Enhancement
  - 13.3.3.1. Ibex Medical launches Galen 3.0 cancer diagnostics platform
  - 13.3.3.2. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
- 13.3.4. Investment & Funding
  - 13.3.4.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
  - 13.3.4.2. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
  - 13.3.4.3. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
- 13.3.5. Award, Recognition, & Expansion
  - 13.3.5.1. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
  - 13.3.5.2. Karkinos Healthcare launches 'Advanced Centre For Cancer Diagnostics and Research'

14. List of Company Mentioned

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing